Nutritional and Metabolic Diseases

Symptoms and General Pathology

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Rare Diseases

Obesity

Breast Neoplasms

Inflammatory Breast Neoplasms

Breast Diseases

Skin Diseases

Overweight

Overnutrition

Nutrition Disorders

Body Weight

Inflammatory Breast Cancer

Performance of measurements of adiposity, extra collection of blood samples

Prospective data and sample collection

Marion Maetens, PhD

Tatjana Geukens, MD

Christine Desmedt, PhD

Giuseppe Floris, MD PhD

FATLAS is a prospective, interventional, non Investigational Medicinal Product (IMP) study aiming to characterize the micro- and macroenvironment of breast cancer according to patient adiposity in different histological and molecular subtypes.

The macroscopic profiling of the patient's adiposity will be based on Body Mass Index (BMI), bioimpedance analysis and waist-to-hip ratio. Blood samples will be taken for lipidomic analyses and for hormonal and immuno assays. Microscopic profiling of adiposity and inflammation will be done on fresh frozen (FF) and Formalin-Fixed Paraffin-Embedded (FFPE) samples from the tumour resection specimen and will consist of histological characterization, immuno assays, multiplex immunohistochemistry, DNA sequencing and single nuclei RNA sequencing both in the tumour and in adjacent normal mammary tissue.

FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.

Calculated: body mass (kg) divided by height squared (m²)

Single nucleus RNA sequencing using 10X Genomics Platform after dissociation of tissue into single nuclei

Number of T-cells per population using immunohistochemical phenotypic markers of cell type and of exhaustion.

Time of activity of different intensities and time of sedentarity, evaluated using the Global Physical Activity Questionnaire (GPAQ) of the World Health Organisation (WHO) (scale: minutes per day, range \[0 - 1440\]). The higher the score for activity the better, the lower the score for sedentarity the better.

Pittsburgh Sleep Quality Index (PSQI) score (range: \[0 - 21\]). Higher scores indicate worse sleep quality.

Nutritional score (natural number, range \[0 - 100\]) calculated using the in-house Food Frequency Questionnaire. A score of \> 70 indicates healthy dietary behaviour.

Food intake in kcal per day calculated using the in-house Food Frequency Questionnaire.

Calculated from multiple frequency bio-impedance measurements (in %, range \[0 - 100\]).

Waist circumference (cm) divided by hip circumference (cm)

In kilograms (kg), measured by handheld dynamometer.

KU Leuven

Universitaire Ziekenhuizen KU Leuven

Digestive System Diseases

Diseases and Abnormalities at or Before Birth

Adenocarcinoma

Stomach Neoplasms

Syndrome

Disease Susceptibility

Neoplastic Syndromes, Hereditary

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Disease Attributes

Stomach Cancer

Diffuse Gastric Cancer

Hereditary Diffuse Gastric Cancer

Subjects with suspicious personal or family medical history of gastric cancer or gastric cancer syndrome.

Jamie Kirkpatrick, R.N.

Jeremy L Davis, M.D.

For more information at the NIH Clinical Center contact National Cancer Institute Referral Office

Background:

Gastric cancers are cancers of the stomach. Hereditary ones are passed from parent to child. Researchers want to gather data about hereditary gastric cancers. They want to learn about changes these cause in the body and about the genes involved.

Objective:

-To gather data about hereditary gastric cancer.

Eligibility:

* People at least 2 years old with personal or family history with a hereditary gastric cancer.
* People at least 2 years old with gene changes that lead to such cancer or a lesion that may be hereditary.

Design:

* Participants will be screened in a separate protocol.
* Participants will have:

  * Physical exam
  * Medical history
  * Blood tests
  * Scans
  * Photos of skin lesions and other findings
  * Gynecology consultation for women
  * Cheek swab (some participants)
* For some participants, their relatives will be asked to join the study.
* Some participants will be asked to allow the study to get stored tissue samples for relatives who have died.
* Some samples will be sent to outside labs. All personal data will be protected. Samples will be destroyed when the study ends.
* Participants will get the results of genetic testing.
* Participants who cannot come to the NIH clinic may just give a cheek swab and have genetic testing done.
* Some participants will be contacted for more testing.

Background:

An estimated 1-3% of gastric cancer cases occur within a familial background as part of an inherited cancer syndrome.

Hereditary Diffuse Gastric Cancer (HDGC) is the most frequent form of familial gastric cancer and has been linked to a germline mutation in the CDH1 gene.

Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) is a more recently described autosomal dominant syndrome characterized by fundic gland polyposis with antral sparing.

Other germline mutations that predispose to gastric cancer such as SDH (succinate dehydrogenase protein subunits) gene and CTNNA1 (alpha catenin).

Objectives:

Characterize the natural and clinical histories of hereditary gastric cancer syndromes.

Eligibility:

Individuals, and family members, who fulfill clinical criteria for a hereditary gastric cancer syndrome irrespective of previous genetic testing or treatment.

Design:

These rare families will be recruited to genetically confirm diagnosis and study the natural history of hereditary gastric cancers.

Genetic testing will be offered to gain appreciation of the effect of mutations on the relative activity of various germline and somatic mutations.

We will determine if there is a relationship between mutation and disease phenotype.

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

.All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.

Characterization of the natural and clinical histories of hereditary gastric cancer syndromes

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.	NCT04200768	Breast Neoplasm...	Prospective dat...	18 Years - 75 Years	Universitaire Ziekenhuizen KU Leuven
FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.	NCT04200768	Breast Neoplasm...	Prospective dat...	18 Years - 75 Years	Universitaire Ziekenhuizen KU Leuven
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer	NCT03030404	Stomach Neoplas... Stomach Cancer Gastric Adenoca... Hereditary Diff... Familial Diffus...		2 Years -	National Institutes of Health Clinical Center (CC)
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer	NCT03030404	Stomach Neoplas... Stomach Cancer Gastric Adenoca... Hereditary Diff... Familial Diffus...		2 Years -	National Institutes of Health Clinical Center (CC)
FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.	NCT04200768	Breast Neoplasm...	Prospective dat...	18 Years - 75 Years	Universitaire Ziekenhuizen KU Leuven
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer	NCT03030404	Stomach Neoplas... Stomach Cancer Gastric Adenoca... Hereditary Diff... Familial Diffus...		2 Years -	National Institutes of Health Clinical Center (CC)

Spots Global Cancer Trial Database for lobular breast cancer